Evidence Explorer · MS-N273 · Supportive physical care · Appraised November 8, 2026
Trials of low-level light or LED photobiomodulation for breast-radiotherapy dermatitis have produced mixed results. One blinded trial was negative; the 71-participant LABRA trial showed an 18-point numerical reduction in grade 2–3 dermatitis that narrowly missed statistical significance; recent reviews judge the evidence promising but uncertain.
Evidence at a glance
- Population: women receiving breast radiotherapy; six-study 2026 review included 233 participants.
- Intervention: protocol-specific low-level light or LED photobiomodulation.
- Comparators: placebo light or standard skin care.
- Key result: LABRA reported grade 2–3 dermatitis in 10% versus 28% at the final session, P=.053; an earlier blinded trial found no reduction.
- Evidence label: mixed, low-certainty and protocol-dependent evidence.
What was studied
LABRA randomized 71 women receiving hypofractionated whole-breast irradiation to standard skin care plus PBM twice weekly or placebo. Severe dermatitis was numerically lower but the trial’s conclusion was negative at the conventional threshold.
A 2026 systematic review found three randomized and three nonrandomized studies with heterogeneous wavelengths, doses and schedules. Four studies were favorable, one was negative, and chronic dermatitis did not clearly improve. MASCC’s radiation-dermatitis review treats PBM as promising rather than settled standard care.
What this evidence cannot establish
Different devices and dosimetry are not interchangeable. Small studies, mixed risk of bias and selective outcomes limit certainty. Improvement in skin grade does not show better local tumor control, survival or protection from late fibrosis.
Safety and practical context
PBM should be delivered under a protocol coordinated with radiation oncology. Eye protection, device calibration, infection control and avoidance of direct use over unassessed lesions matter. It must not delay assessment of moist desquamation, infection, severe pain or treatment interruption.
Questions for the care team
- Which wavelength, dose, timing and device match the clinical evidence?
- Is the goal prevention of peak dermatitis, faster healing or pain relief?
- How will the radiation team document skin grade and decide whether to continue?
Sources and identifiers
- LABRA randomized trial — PMID 34481420
- Earlier double-blind negative trial — PMID 21070458
- 2026 systematic review — PMID 41706328
- MASCC systematic review and guideline evidence base — PMID 37181415
Funding and conflicts: Funding and conflicts differed across studies; complete study-level details were not verified for every component report.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
